Zelluna Immunotherapy (ZLNA.OL)

Executive Summary

Zelluna Immunotherapy is a Norwegian biotech company pioneering a novel class of cell therapies that combine T cell receptor (TCR) specificity with natural killer (NK) cell effector functions (TCR-NK) to target solid tumors. Founded in 2016 and publicly traded on the Oslo Stock Exchange (ZLNA.OL), the company addresses key limitations of conventional cell therapies, such as CAR-T, in solid tumors, including poor tumor infiltration, antigen escape, and immunosuppressive microenvironments. Zelluna's platform leverages allogeneic NK cells engineered with tumor-specific TCRs, offering potential off-the-shelf availability, enhanced tumor targeting, and reduced toxicity. The company's lead candidate targets a validated tumor-associated antigen and is being evaluated in early-phase clinical trials. With a strong intellectual property portfolio and a focus on high unmet need indications, Zelluna is positioned to compete in the rapidly evolving cell therapy landscape. Its recent public listing provides capital to advance its pipeline, though the company remains in early development stages with no approved products. The success of its platform hinges on demonstrating clinical proof-of-concept, manufacturing scalability, and safety differentiation from existing therapies.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2 interim data readout for lead TCR-NK candidate in solid tumors40% success
• Q4 2026Initiation of first-in-human trial for second pipeline candidate60% success
• H1 2027Strategic partnership for manufacturing or co-development50% success